Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease?

Ageing Research Reviews

Volumn 13, Issue 1, 2014, Pages 107-114

  Bisaglia, Marco ^a   Filograna, Roberta ^a   Beltramini, Mariano ^a   Bubacco, Luigi ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Dopamine; Dopamine quinones; Mitochondria; Oxidative stress; Parkinson's disease

Indexed keywords

DOPAMINE; DOPAMINE DERIVATIVE; DOPAMINE DERIVED QUINONE; FREE RADICAL; QUINONE DERIVATIVE; UNCLASSIFIED DRUG;

CHEMICAL REACTION; CLEARANCE; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; MEDICAL LITERATURE; MITOCHONDRION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN TARGETING; REVIEW;

DOPAMINE; DOPAMINE-QUINONES; MITOCHONDRIA; OXIDATIVE STRESS; PARKINSON'S DISEASE;

ANIMALS; BRAIN; DISEASE PROGRESSION; DOPAMINE; DOPAMINERGIC NEURONS; HUMANS; MITOCHONDRIA; NERVE DEGENERATION; OXIDATION-REDUCTION; OXIDATIVE STRESS; PARKINSON DISEASE; SIGNAL TRANSDUCTION;

EID: 84892954173     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2013.12.009     Document Type: Review

References (109)

1. Alam Z.I., Daniel S.E., Lees A.J., Marsden D.C., Jenner P., Halliwell B. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem. 1997, 69:1326-1329.
2. Beal M.F. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann. N. Y. Acad. Sci. 2003, 991:120-131.
3. Belluzzi E., Bisaglia M., Lazzarini E., Tabares L.C., Beltramini M., Bubacco L. Human SOD2 modification by dopamine quinones affects enzymatic activity by promoting its aggregation: possible implications for Parkinson's disease. PLoS One 2012, 7:e38026.
4. Berman S.B., Hastings T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem. 1999, 73:1127-1137.
5. Bisaglia M., Mammi S., Bubacco L. Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alpha-synuclein. J. Biol. Chem. 2007, 282:15597-15605.
6. Bisaglia M., Soriano M.E., Arduini I., Mammi S., Bubacco L. Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: implications for mitochondrial dysfunction in Parkinson disease. Biochim. Biophys. Acta 2010, 1802:699-706.
7. Bisaglia M., Tosatto L., Munari F., Tessari I., de Laureto P.P., Mammi S., Bubacco L. Dopamine quinones interact with alpha-synuclein to form unstructured adducts. Biochem. Biophys. Res. Commun. 2010, 394:424-428.
8. Bishop S.P., Anderson P.G., Tucker D.C. Morphological development of the rat heart growing in oculo in the absence of hemodynamic work load. Circ. Res. 1990, 66:84-102.
9. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., Dekker M.C., Squitieri F., Ibanez P., Joosse M., van Dongen J.W., Vanacore N., van Swieten J.C., Brice A., Meco G., van Duijn C.M., Oostra B.A., Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003, 299:256-259.
10. Bove J., Perier C. Neurotoxin-based models of Parkinson's disease. Neuroscience 2012, 211:51-76.
11. Bueler H. Mitochondrial dynamics, cell death and the pathogenesis of Parkinson's disease. Apoptosis 2010, 15:1336-1353.
12. Cappai R., Leck S.L., Tew D.J., Williamson N.A., Smith D.P., Galatis D., Sharples R.A., Curtain C.C., Ali F.E., Cherny R.A., Culvenor J.G., Bottomley S.P., Masters C.L., Barnham K.J., Hill A.F. Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J. 2005, 19:1377-1379.
13. Chartier-Harlin M.C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., Levecque C., Larvor L., Andrieux J., Hulihan M., Waucquier N., Defebvre L., Amouyel P., Farrer M., Destee A. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1167-1169.
14. Chen J., Li L., Chin L.S. Parkinson disease protein DJ-1 converts from a zymogen to a protease by carboxyl-terminal cleavage. Hum. Mol. Genet. 2010, 19:2395-2408.
15. Cohen G., Farooqui R., Kesler N. Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:4890-4894.
16. Cohen G., Kesler N. Monoamine oxidase and mitochondrial respiration. J. Neurochem. 1999, 73:2310-2315.
17. Conway K.A., Rochet J.C., Bieganski R.M., Lansbury P.T. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 2001, 294:1346-1349.
18. Cookson M.R. Parkinsonism due to mutations in PINK1, parkin, and DJ-1 and oxidative stress and mitochondrial pathways. Cold Spring Harb. Perspect. Med. 2012, 2:a009415.
19. Cuervo A.M., Stefanis L., Fredenburg R., Lansbury P.T., Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004, 305:1292-1295.
20. da Costa C.A. DJ-1: a newcomer in Parkinson's disease pathology. Curr. Mol. Med. 2007, 7:650-657.
21. Eisenhofer G., Kopin I.J., Goldstein D.S. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol. Rev. 2004, 56:331-349.
22. Exner N., Treske B., Paquet D., Holmstrom K., Schiesling C., Gispert S., Carballo-Carbajal I., Berg D., Hoepken H.H., Gasser T., Kruger R., Winklhofer K.F., Vogel F., Reichert A.S., Auburger G., Kahle P.J., Schmid B., Haass C. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J. Neurosci. 2007, 27:12413-12418.
23. Floor E., Wetzel M.G. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J. Neurochem. 1998, 70:268-275.
24. Fornstedt B., Rosengren E., Carlsson A. Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species. Neuropharmacology 1986, 25:451-454.
25. Gimenez-Xavier P., Gomez-Santos C., Castano E., Francisco R., Boada J., Unzeta M., Sanz E., Ambrosio S. The decrease of NAD(P)H has a prominent role in dopamine toxicity. Biochim. Biophys. Acta 2006, 1762:564-574.
26. Girotto S., Sturlese M., Bellanda M., Tessari I., Cappellini R., Bisaglia M., Bubacco L., Mammi S. Dopamine-derived quinones affect the structure of the redox sensor DJ-1 through modifications at Cys-106 and Cys-53. J. Biol. Chem. 2012, 287:18738-18749.
27. Gluck M., Ehrhart J., Jayatilleke E., Zeevalk G.D. Inhibition of brain mitochondrial respiration by dopamine: involvement of H(2)O(2) and hydroxyl radicals but not glutathione-protein-mixed disulfides. J. Neurochem. 2002, 82:66-74.
28. Gluck M.R., Zeevalk G.D. Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson's disease and catecholamine-associated diseases. J. Neurochem. 2004, 91:788-795.
29. Goldstein D.S., Sullivan P., Holmes C., Kopin I.J., Basile M.J., Mash D.C. Catechols in post-mortem brain of patients with Parkinson disease. Eur. J. Neurol. 2011, 18:703-710.
30. Gutman M., Mersmann H., Luthy J., Singer T.P. Action of sulfhydryl inhibitors on different forms of the respiratory chain-linked reduced nicotinamide-adenine dinucleotide dehydrogenase. Biochemistry 1970, 9:2678-2687.
31. Hastings T.G., Lewis D.A., Zigmond M.J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:1956-1961.
32. Hastings T.G., Zigmond M.J. Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites. J. Neural. Transm. Suppl. 1997, 49:103-110.
33. Hauser D.N., Dukes A.A., Mortimer A.D., Hastings T.G. Dopamine quinone modifies and decreases the abundance of the mitochondrial selenoprotein glutathione peroxidase 4. Free Radic. Biol. Med. 2013, 65C:419-427.
34. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 2009, 8:382-397.
35. Hirsch E.C., Hunot S., Hartmann A. Neuroinflammatory processes in Parkinson's disease. Parkinsonism Relat. Disord. 2005, 11(Suppl 1):S9L S15.
36. Iversen S.D., Iversen L.L. Dopamine: 50 years in perspective. Trends Neurosci. 2007, 30:188-193.
37. Jinsmaa Y., Florang V.R., Rees J.N., Mexas L.M., Eckert L.L., Allen E.M., Anderson D.G., Doorn J.A. Dopamine-derived biological reactive intermediates and protein modifications: implications for Parkinson's disease. Chem. Biol. Interact. 2011, 192:118-121.
38. Junn E., Taniguchi H., Jeong B.S., Zhao X., Ichijo H., Mouradian M.M. Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:9691-9696.
39. Khan F.H., Sen T., Maiti A.K., Jana S., Chatterjee U., Chakrabarti S. Inhibition of rat brain mitochondrial electron transport chain activity by dopamine oxidation products during extended in vitro incubation: implications for Parkinson's disease. Biochim. Biophys. Acta 2005, 1741:65-74.
40. Kim C., Ho D.H., Suk J.E., You S., Michael S., Kang J., Joong Lee S., Masliah E., Hwang D., Lee H.J., Lee S.J. Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat. Commun. 2013, 4:1562.
41. Kim W.G., Mohney R.P., Wilson B., Jeohn G.H., Liu B., Hong J.S. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J. Neurosci. 2000, 20:6309-6316.
42. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392:605-608.
43. Klegeris A., Korkina L.G., Greenfield S.A. Autoxidation of dopamine: a comparison of luminescent and spectrophotometric detection in basic solutions. Free Radic. Biol. Med. 1995, 18:215-222.
44. Kuhn D.M., Arthur R.E., Thomas D.M., Elferink L.A. Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease. J. Neurochem. 1999, 73:1309-1317.
45. Kuhn D.M., Francescutti-Verbeem D.M., Thomas D.M. Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: relationship to methamphetamine-induced nerve ending damage. Ann. N. Y. Acad. Sci. 2006, 1074:31-41.
46. LaVoie M.J., Hastings T.G. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J. Neurosci. 1999, 19:1484-1491.
47. LaVoie M.J., Ostaszewski B.L., Weihofen A., Schlossmacher M.G., Selkoe D.J. Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. 2005, 11:1214-1221.
48. Le W., Rowe D., Xie W., Ortiz I., He Y., Appel S.H. Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J. Neurosci. 2001, 21:8447-8455.
49. Lee F.J., Liu F. Genetic factors involved in the pathogenesis of Parkinson's disease. Brain Res. Rev. 2008, 58:354-364.
50. Leong S.L., Cappai R., Barnham K.J., Pham C.L. Modulation of alpha-synuclein aggregation by dopamine: a review. Neurochem. Res. 2009, 34:1838-1846.
51. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M.J., Jonnalagada S., Chernova T., Dehejia A., Lavedan C., Gasser T., Steinbach P.J., Wilkinson K.D., Polymeropoulos M.H. The ubiquitin pathway in Parkinson's disease. Nature 1998, 395:451-452.
52. Lestienne P., Nelson J., Riederer P., Jellinger K., Reichmann H. Normal mitochondrial genome in brain from patients with Parkinson's disease and complex I defect. J. Neurochem. 1990, 55:1810-1812.
53. Levay G., Bodell W.J. Detection of dopamine-DNA adducts: potential role in Parkinson's disease. Carcinogenesis 1993, 14:1241-1245.
54. Li H.T., Lin D.H., Luo X.Y., Zhang F., Ji L.N., Du H.N., Song G.Q., Hu J., Zhou J.W., Hu H.Y. Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein, Implication for dopaminergic neurodegeneration. FEBS J. 2005, 272:3661-3672.
55. Li J., Zhu M., Manning-Bog A.B., Di Monte D.A., Fink A.L. Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB J. 2004, 18:962-964.
56. Lull M.E., Block M.L. Microglial activation and chronic neurodegeneration. Neurotherapeutics 2010, 7:354-365.
57. Marchitti S.A., Deitrich R.A., Vasiliou V. Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol. Rev. 2007, 59:125-150.
58. Martinez-Vicente M., Talloczy Z., Kaushik S., Massey A.C., Mazzulli J., Mosharov E.V., Hodara R., Fredenburg R., Wu D.C., Follenzi A., Dauer W., Przedborski S., Ischiropoulos H., Lansbury P.T., Sulzer D., Cuervo A.M. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J. Clin. Invest. 2008, 118:777-788.
59. Mazzulli J.R., Armakola M., Dumoulin M., Parastatidis I., Ischiropoulos H. Cellular oligomerization of alpha-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence. J. Biol. Chem. 2007, 282:31621-31630.
60. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
61. Mogi M., Harada M., Narabayashi H., Inagaki H., Minami M., Nagatsu T. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci. Lett. 1996, 211:13-16.
62. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 1994, 165:208-210.
63. Murphy M.P. How mitochondria produce reactive oxygen species. Biochem. J. 2009, 417:1-13.
64. Narendra D., Tanaka A., Suen D.F., Youle R.J. Parkin-induced mitophagy in the pathogenesis of Parkinson disease. Autophagy 2009, 5:706-708.
65. Nimmerjahn A., Kirchhoff F., Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308:1314-1318.
66. Norris E.H., Giasson B.I., Hodara R., Xu S., Trojanowski J.Q., Ischiropoulos H., Lee V.M. Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J. Biol. Chem. 2005, 280:21212-21219.
67. Olzmann J.A., Brown K., Wilkinson K.D., Rees H.D., Huai Q., Ke H., Levey A.I., Li L., Chin L.S. Familial Parkinson's disease-associated L166P mutation disrupts DJ-1 protein folding and function. J. Biol. Chem. 2004, 279:8506-8515.
68. Owen A.D., Schapira A.H., Jenner P., Marsden C.D. Oxidative stress and Parkinson's disease. Ann. N. Y. Acad. Sci. 1996, 786:217-223.
69. Pogson J.H., Ivatt R.M., Whitworth A.J. Molecular mechanisms of PINK1-related neurodegeneration. Curr. Neurol. Neurosci. Rep. 2011, 11:283-290.
70. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
71. Qian L., Flood P.M., Hong J.S. Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy. J. Neural Transm. 2010, 117:971-979.
72. Rees J.N., Florang V.R., Eckert L.L., Doorn J.A. Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol. Chem. Res. Toxicol. 2009, 22:1256-1263.
73. Rekas A., Knott R.B., Sokolova A., Barnham K.J., Perez K.A., Masters C.L., Drew S.C., Cappai R., Curtain C.C., Pham C.L. The structure of dopamine induced alpha-synuclein oligomers. Eur. Biophys. J. 2010, 39:1407-1419.
74. Ross C.A., Poirier M.A. Opinion: what is the role of protein aggregation in neurodegeneration?. Nat. Rev. Mol. Cell Biol. 2005, 6:891-898.
75. Rubinsztein D.C. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006, 443:780-786.
76. Rumchev K., Spickett J., Bulsara M., Phillips M., Stick S. Association of domestic exposure to volatile organic compounds with asthma in young children. Thorax 2004, 59:746-751.
77. Sanders L.H., Greenamyre J.T. Oxidative damage to macromolecules in human Parkinson disease and the rotenone model. Free Radic. Biol. Med. 2013, 62:111-120.
78. Schapira A.H. Oxidative stress in Parkinson's disease. Neuropathol. Appl. Neurobiol. 1995, 21:3-9.
79. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 1990, 54:823-827.
80. Schapira A.H., Cooper J.M., Dexter D., Jenner P., Clark J.B., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989, 1:1269.
81. Shen J., Cookson M.R. Mitochondria and dopamine: new insights into recessive parkinsonism. Neuron 2004, 43:301-304.
82. Shendelman S., Jonason A., Martinat C., Leete T., Abeliovich A. DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol. 2004, 2:e362.
83. Shults C.W. Lewy bodies. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:1661-1668.
84. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., Gwinn-Hardy K. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
85. Spencer J.P., Jenner P., Daniel S.E., Lees A.J., Marsden D.C., Halliwell B. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J. Neurochem. 1998, 71:2112-2122.
86. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
87. Streit W.J. Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 2002, 40:133-139.
88. Sulzer D., Bogulavsky J., Larsen K.E., Behr G., Karatekin E., Kleinman M.H., Turro N., Krantz D., Edwards R.H., Greene L.A., Zecca L. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:11869-11874.
89. Sulzer D., Zecca L. Intraneuronal dopamine-quinone synthesis: a review. Neurotox. Res. 2000, 1:181-195.
90. Theodore S., Cao S., McLean P.J., Standaert D.G. Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J. Neuropathol. Exp. Neurol. 2008, 67:1149-1158.
91. Tse D.C., McCreery R.L., Adams R.N. Potential oxidative pathways of brain catecholamines. J. Med. Chem. 1976, 19:37-40.
92. Valente E.M., Salvi S., Ialongo T., Marongiu R., Elia A.E., Caputo V., Romito L., Albanese A., Dallapiccola B., Bentivoglio A.R. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann. Neurol. 2004, 56:336-341.
93. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007, 39:44-84.
94. Van Laar V.S., Dukes A.A., Cascio M., Hastings T.G. Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease. Neurobiol. Dis. 2008, 29:477-489.
95. Van Laar V.S., Mishizen A.J., Cascio M., Hastings T.G. Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neurobiol. Dis. 2009, 34:487-500.
96. Volles M.J., Lansbury P.T. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 2003, 42:7871-7878.
97. Wang N., Wang Y., Yu G., Yuan C., Ma J. Quinoprotein adducts accumulate in the substantia nigra of aged rats and correlate with dopamine-induced toxicity in SH-SY5Y cells. Neurochem. Res. 2011, 36:2169-2175.
98. Wey M.C., Fernandez E., Martinez P.A., Sullivan P., Goldstein D.S., Strong R. Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease. PLoS One 2012, 7:e31522.
99. Wood S.J., Wypych J., Steavenson S., Louis J.C., Citron M., Biere A.L. alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 1999, 274:19509-19512.
100. Xu J., Zhong N., Wang H., Elias J.E., Kim C.Y., Woldman I., Pifl C., Gygi S.P., Geula C., Yankner B.A. The Parkinson's disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis. Hum. Mol. Genet. 2005, 14:1231-1241.
101. Xu Y., Stokes A.H., Roskoski R., Vrana K.E. Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. J. Neurosci. Res. 1998, 54:691-697.
102. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E.R., Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:2696-2701.
103. Zafar K.S., Siegel D., Ross D. A potential role for cyclized quinones derived from dopamine, DOPA, and 3,4-dihydroxyphenylacetic acid in proteasomal inhibition. Mol. Pharmacol. 2006, 70:1079-1086.
104. Zahid M., Saeed M., Yang L., Beseler C., Rogan E., Cavalieri E.L. Formation of dopamine quinone-DNA adducts and their potential role in the etiology of Parkinson's disease. IUBMB Life 2011, 63:1087-1093.
105. Zecca L., Zucca F.A., Albertini A., Rizzio E., Fariello R.G. A proposed dual role of neuromelanin in the pathogenesis of Parkinson's disease. Neurology 2006, 67:S8-S11.
106. Zecca L., Zucca F.A., Wilms H., Sulzer D. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci. 2003, 26:578-580.
107. Zhang J., Perry G., Smith M.A., Robertson D., Olson S.J., Graham D.G., Montine T.J. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am. J. Pathol. 1999, 154:1423-1429.
108. Zhang W., Wang T., Pei Z., Miller D.S., Wu X., Block M.L., Wilson B., Zhou Y., Hong J.S., Zhang J. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 2005, 19:533-542.
109. Zhou Z.D., Lim T.M. Dopamine (DA) induced irreversible proteasome inhibition via DA derived quinones. Free Radic. Res. 2009, 43:417-430.